Associated Papers
Reliability of Tumor Testing Compared to Germline Testing for Detecting BRCA1 and BRCA2 Mutations in Patients with Epithelial Ovarian Cancer.
Bekos C et al.
Journal of Personalized Medicine, 2021
BRCA1 and BRCA2 founder mutations account for 78% of germline carriers among hereditary breast cancer families in Chile.
Alvarez C et al.
Oncotarget, 2017
Genetic predisposition to gastric cancer.
Petrovchich I et al.
Seminars in Oncology, 2016
Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers.
Domagala P et al.
Plos One, 2015
BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland.
Ratajska M et al.
Oncology Reports, 2008
Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
Gallardo M et al.
Breast Cancer Research and Treatment, 2006
[Determination of a BRCA1 gene mutation in a family with hereditary breast cancer].
Gallardo M et al.
Revista Medica De Chile, 2004
Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors.
Tapia T et al.
Epigenetics, 0
Select a paper to view details